Repligen Co. (NASDAQ:RGEN) Shares Purchased by Harbor Investment Advisory LLC

Harbor Investment Advisory LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 289.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,929 shares of the biotechnology company's stock after purchasing an additional 2,176 shares during the quarter. Harbor Investment Advisory LLC's holdings in Repligen were worth $373,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in RGEN. CIBC Asset Management Inc lifted its stake in shares of Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 81 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after acquiring an additional 100 shares during the last quarter. Utah Retirement Systems boosted its stake in Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 100 shares during the last quarter. Peapack Gladstone Financial Corp increased its holdings in Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after buying an additional 103 shares during the last quarter. Finally, Signaturefd LLC raised its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In other news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on RGEN. HC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. Finally, Canaccord Genuity Group reduced their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Repligen Stock Performance

RGEN stock traded up $1.60 during midday trading on Friday, reaching $128.30. 599,466 shares of the company's stock traded hands, compared to its average volume of 749,368. The company has a 50-day moving average price of $127.27 and a two-hundred day moving average price of $143.41. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52 week low of $102.97 and a 52 week high of $182.52. The firm has a market capitalization of $7.21 billion, a PE ratio of -251.57, a price-to-earnings-growth ratio of 4.54 and a beta of 1.10.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the prior year, the company earned $0.28 earnings per share. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.